Actively Recruiting
Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors
Led by Stanford University · Updated on 2025-12-24
100
Participants Needed
1
Research Sites
644 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research trial studies using genomic profiling to recommend anticancer treatment to patients with cancer that has spread beyond the original site of the tumor (metastatic cancer). Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect genetic changes or abnormalities. This information can then be used to recommend treatments that may be more likely to result in a beneficial response. It is not yet known whether genomic profiling will detect abnormalities that can be used to make treatment recommendations and whether treatment based on genomic profiling is more effective than standard treatment.
CONDITIONS
Official Title
Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand and provide written informed consent and HIPAA authorization before any study procedures
- Have metastatic, incurable cancer and progressed on at least one systemic therapy or have cancer without standard first-line therapy
- Have measurable disease according to RECIST 1.1 criteria
- Have an ECOG performance status of 0 or 1
- Be medically suitable and willing to undergo biopsy or have adequate archival tissue available for profiling
- Female patients of childbearing potential must have a negative pregnancy test and agree to use contraception during and for one month after treatment
- Male patients must use barrier contraception during and for one month after treatment
You will not qualify if you...
- Have lesions inaccessible or not planned for biopsy and insufficient archival tissue for profiling
- Have a diagnosis of hematologic malignancy
- Have symptomatic central nervous system metastases unless stable and off or on stable steroids for at least 2 weeks
- Have uncontrolled serious illnesses such as active infection, heart failure, unstable angina, arrhythmias, psychiatric illness, or conditions limiting study compliance
- Have known HIV, hepatitis B, or hepatitis C infection
- Are pregnant, breastfeeding, or a patient of childbearing potential not using adequate contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University
Palo Alto, California, United States, 94305
Actively Recruiting
Research Team
R
Rozelle Laquindanum
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here